Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (3107)	5/26/1999 6:33:00 AM
From: Roger Mathias	Respond to of 3702

Davis, glad you're back!

To: EZLibra who wrote (3107)	5/26/1999 8:36:00 AM
From: john dixon	Read Replies (1) \| Respond to of 3702

Davis, my main man. Good to have you back. Sorry your bid for the Redskins didn't go through. Good luck sailing and fishing this summer. What are your thoughts on the application for accelerated approval for Cotara? To the point, do you think we will get it?

To: EZLibra who wrote (3107)	5/31/1999 3:51:00 AM
From: Maurice Winn	Respond to of 3702

<...about half of cancer therapy in the U.S. is off-label use... > Hello Davis, welcome back. That sounds a fairly anarchic approach to use of cancer therapy. You mean to say those off-label applications are experiments by oncologists using their judgement without multithousands of statistically linearly regressed double blind trials to prove their scientific validity? That isn't what I'm hearing around these parts as the most desirable way to approach treatment. I suppose it is tacit admission that the FDA centrally planned medical determinations are inadequate for the real world where people die before products are approved, so experiments by knowledgeable experts with the informed agreement of their customers is the better way to handle survival for cancer victims. Maurice